Amicus Therapeutics Inc (FOLD)
10.49
+0.07
(+0.67%)
USD |
NASDAQ |
May 03, 14:53
Amicus Therapeutics Cash from Financing (Quarterly): 8.21M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.21M |
| September 30, 2023 | 37.62M |
| June 30, 2023 | 23.67M |
| March 31, 2023 | -7.825M |
| December 31, 2022 | 0.557M |
| September 30, 2022 | -0.559M |
| June 30, 2022 | 0.693M |
| March 31, 2022 | -8.154M |
| December 31, 2021 | -0.104M |
| September 30, 2021 | 201.11M |
| June 30, 2021 | 2.235M |
| March 31, 2021 | 8.829M |
| December 31, 2020 | 21.55M |
| September 30, 2020 | 238.71M |
| June 30, 2020 | 4.086M |
| March 31, 2020 | -1.487M |
| December 31, 2019 | 3.191M |
| September 30, 2019 | 0.523M |
| June 30, 2019 | 196.40M |
| March 31, 2019 | 17.38M |
| December 31, 2018 | 0.359M |
| September 30, 2018 | 146.80M |
| June 30, 2018 | 7.033M |
| March 31, 2018 | 296.58M |
| December 31, 2017 | 6.864M |
| Date | Value |
|---|---|
| September 30, 2017 | 250.19M |
| June 30, 2017 | -9.524M |
| March 31, 2017 | -0.095M |
| December 31, 2016 | 150.32M |
| September 30, 2016 | 39.64M |
| June 30, 2016 | 83.26M |
| March 31, 2016 | -0.502M |
| December 31, 2015 | 0.151M |
| September 30, 2015 | 53.50M |
| June 30, 2015 | 233.18M |
| March 31, 2015 | 4.063M |
| December 31, 2014 | 98.64M |
| September 30, 2014 | 22.36M |
| June 30, 2014 | 18.26M |
| March 31, 2014 | -0.085M |
| December 31, 2013 | 29.68M |
| September 30, 2013 | -0.10M |
| June 30, 2013 | -0.099M |
| March 31, 2013 | -0.10M |
| December 31, 2012 | 0.461M |
| September 30, 2012 | 17.85M |
| June 30, 2012 | -0.416M |
| March 31, 2012 | 63.58M |
| December 31, 2011 | -0.313M |
| September 30, 2011 | -0.303M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-8.154M
Minimum
Mar 2022
238.71M
Maximum
Sep 2020
38.38M
Average
3.191M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
| TG Therapeutics Inc | -0.001M |
| Geron Corp | 33.28M |
| Vanda Pharmaceuticals Inc | 0.00 |
| Fate Therapeutics Inc | -0.18M |
| Editas Medicine Inc | 0.514M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.458M |
| Cash from Investing (Quarterly) | -23.96M |
| Free Cash Flow | -76.53M |
| Free Cash Flow Per Share (Quarterly) | 0.0057 |
| Free Cash Flow to Equity (Quarterly) | 7.94M |
| Free Cash Flow to Firm (Quarterly) | 13.65M |
| Free Cash Flow Yield | -2.47% |